<DOC>
	<DOC>NCT02308865</DOC>
	<brief_summary>Single-center, prospective, controlled, open-label, randomized, two parallel arms comparing early Palliative care versus Standard care in patients with non-small-cell metastatic lung cancer</brief_summary>
	<brief_title>Early Palliative Care in Metastatic Lung Cancer in Northern France</brief_title>
	<detailed_description>144 patients will be included; 72 per arm. - "Standard" Control arm: patient supported by the onco-respiratory service. - Intervention arm: patients benefit from early palliative care in addition to standard onco-pneumologic care. The main criterion of judgment is the TOI score measured at 12 weeks. FACTL questionnaires, HADS and PHQ-9 will be filled out before randomization , at 12 weeks and 21 weeks</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Being diagnosed with nonsmall cell lung cancer Proven histologically Metastatic proven imaging (MRI, CT Scanner, PET scan) Stage IV (any T, any N, M1) prior to secondary chemotherapy treatment. Age&gt; 18 years PS â‰¤2 Patient able to understand the nature, purpose and methodology of the study signed Informed consent Age &lt;18 years Patient already supported by palliative care Patient with an activating EGFR mutation or EML4ALK rearrangement Patient under trusteeship / guardianship</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Early palliative care</keyword>
	<keyword>Lung cancer</keyword>
	<keyword>Quality of life</keyword>
</DOC>